# Bio-Techne **Source:** https://geo.sig.ai/brands/bio-techne **Vertical:** Healthcare Tech **Subcategory:** Enterprise **Tier:** Leader **Website:** bio-techne.com **Last Updated:** 2026-04-14 ## Summary Minneapolis life science tools (NASDAQ: TECH) at $1.19B FY2024 revenue; Q2 FY2025 9% organic growth, R&D Systems cytokines/antibodies + RNAscope spatial biology (500K+ products) competing with Thermo Fisher for biopharma reagents. ## Company Overview Bio-Techne Corporation is a Minneapolis, Minnesota-based life sciences tools company — publicly traded on NASDAQ (NASDAQ: TECH) as an S&P 500 Health Care component — developing, manufacturing, and selling biological reagents, proteins, antibodies, assay kits, analytical instruments, and spatial biology tools for pharmaceutical drug discovery, bioprocessing, academic research, and clinical diagnostics through approximately 3,000 employees across 34 global locations with an annual revenue of $1.19 billion in fiscal year 2024. In Q2 fiscal 2025, Bio-Techne reported organic revenue growth of 9% to $297 million, demonstrating recovery from the funding-constrained biotech environment of 2023-2024. The company operates through two segments: Protein Sciences (approximately 75% of revenue, including the R&D Systems portfolio of 500,000+ life science products — cytokines, growth factors, antibodies, ELISAs, and recombinant proteins — as well as ProteinSimple analytical instruments and Tocris Bioscience chemical biology tools) and Diagnostics and Genomics (approximately 25%, including Advanced Cell Diagnostics' RNAscope technology for gene expression visualization in intact tissue and Lunaphore's COMET spatial biology automation platform acquired in 2023). Bio-Techne launched approximately 800 new products in fiscal 2024 and maintains a catalog of 6,000+ recombinant proteins spanning 35 species. The company has a market capitalization of approximately $9.59 billion. Bio-Techne's life science tools model addresses the biological reagent reproducibility and traceability problem that pharmaceutical and academic researchers face when conducting experiments that must be repeated across years, labs, and geographies: a drug discovery team screening compounds for activity against a cytokine target (e.g., IL-6, TNF-alpha) requires reference proteins and antibody reagents that perform consistently lot-to-lot, species-to-species, and assay-to-assay — otherwise, a lead compound validated in Year 1 may fail in Year 3 because the reference protein standard used to measure activity degraded or changed manufacturing process. R&D Systems' position as the gold-standard supplier for cytokine proteins and ELISA kits (used in published peer-reviewed papers across 25,000+ publications) creates the citation network that makes switching to a lower-cost reagent supplier a scientific risk that academic and biopharma researchers prefer to avoid. The RNAscope spatial biology platform (enabling visualization of RNA expression in specific cells within intact tissue sections rather than bulk RNA-seq that averages across thousands of cells) addresses the drug developer's need to understand drug target expression at cellular resolution within tumor microenvironments and brain tissue. In 2025, Bio-Techne competes in the life science reagents, protein biology, and spatial biology tools market with Thermo Fisher Scientific (NYSE: TMO, $43B revenue, Invitrogen/Gibco life science tools), Merck KGaA/MilliporeSigma (private, laboratory chemicals and biologics, €22B revenue), and 10x Genomics (NASDAQ: TXG, spatial transcriptomics platforms, $157M revenue) for biopharma research account penetration, academic core lab adoption, and pharmaceutical quality control reagent supply. Bio-Techne's high-margin reagent model (catalog life science products sold to research labs at gross margins of 70%+) is more durable than instrument hardware because consumable reagent purchasing decisions are made at the bench scientist level based on scientific validation rather than IT procurement cycles. The COMET spatial biology platform (Lunaphore, 2023 acquisition) positions Bio-Techne against 10x Genomics and Akoya Biosciences in the high-growth tissue spatial biology market that pharmaceutical companies use for biomarker discovery and drug mechanism of action studies. The 2025 strategy focuses on resuming organic growth momentum after 2023-2024 biotech funding headwinds, expanding the spatial biology platform into clinical research and companion diagnostics, and growing the bioprocessing reagents business as cell therapy manufacturing scales. ## Frequently Asked Questions ### What does Bio-Techne do? Bio-Techne is a global life sciences company that develops, manufactures, and sells innovative reagents, instruments, and services for research, diagnostic, and bioprocessing markets. The company provides over 500,000 products including antibodies, proteins, assays, and analytical instruments through prestigious brands like R&D Systems, Novus Biologicals, Tocris Bioscience, and ProteinSimple. Bio-Techne serves pharmaceutical, biotechnology, academic, and diagnostic laboratories worldwide. ### Who are Bio-Techne's customers and target market? Bio-Techne serves a diverse customer base including pharmaceutical companies, biotechnology firms, academic research institutions, hospital laboratories, and diagnostic testing facilities. The company's products are used by researchers studying cancer, immunology, neuroscience, stem cells, and other areas of biomedical science. Bio-Techne has clients in over 100 countries and operates 34 locations worldwide to serve the global life sciences community. ### When was Bio-Techne founded? Bio-Techne was founded in 1976 by Roger C. Lucas and co-founders as Research and Diagnostic Systems, Inc. The company merged with Techne Corporation in 1985 and went public. In February 2014, the company rebranded as Bio-Techne Corporation to reflect its evolution and the breadth of its biotechnology offerings. ### Where is Bio-Techne based? Bio-Techne is headquartered at 614 McKinley Place NE, Suite 1500, Minneapolis, Minnesota 55413, USA. The company maintains a global presence with over 3,000 employees across 34 locations in multiple countries, serving clients worldwide in the life sciences industry. ### What are Bio-Techne's key financial metrics? In fiscal year 2024, Bio-Techne reported revenue of $1.19 billion (up from $1.14 billion in 2023), with a market capitalization of approximately $9.59 billion. The company generated $299 million in operating cash flow and $224 million in free cash flow. Bio-Techne employs approximately 3,100 people globally and maintains a gross margin of 66.84%. ### What makes Bio-Techne different from competitors? Bio-Techne differentiates itself through its proprietary RNAscope technology for single-molecule RNA detection, its COMET automated spatial biology platform, and its extensive catalog of over 500,000 validated products. The company's integration of multiple premier brands (R&D Systems, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics) provides comprehensive solutions from reagents to instruments. Bio-Techne launches approximately 800 new products annually and maintains strong expertise in spatial biology and personalized medicine diagnostics. ### Who are Bio-Techne's main competitors? Bio-Techne competes with other life sciences companies including Abcam, Thermo Fisher Scientific, Luminex, Stem Cell Technologies, and Merck (through its life science division). The company's subsidiaries like Novus Biologicals compete directly with these firms in antibody and reagent markets. Bio-Techne's market position as a leader in spatial biology and its comprehensive product portfolio give it competitive advantages. ### How can I contact Bio-Techne? You can contact Bio-Techne at their headquarters: 614 McKinley Place NE, Minneapolis, MN 55413, USA. Phone: +1 612-379-8854. For career opportunities, email talent.acquisition@bio-techne.com. Visit their website at www.bio-techne.com for product information, technical support, and general inquiries. Be aware that all official Bio-Techne employment offers come through the Workday candidate portal or personal phone calls. ### Is Bio-Techne hiring? Yes, Bio-Techne actively recruits talent across its global operations. The company offers careers in research and development, manufacturing, sales, marketing, and corporate functions. Visit bio-techne.com/about/careers to explore current opportunities. Recent openings have included positions such as Corporate Employment Counsel in Minneapolis. All legitimate job offers are delivered through the Workday portal or direct phone calls from Bio-Techne representatives. ### What's the latest news about Bio-Techne? Recent developments include Bio-Techne's Q2 fiscal 2025 results showing 9% organic revenue growth to $297 million, the announcement of selling its Exosome Diagnostics business to Mdxhealth for $15 million (expected to close Q1 fiscal 2026), and strategic partnerships with Spear Bio for ultrasensitive biomarker detection and with U.S. Pharmacopeia for monoclonal antibody reference standards. The company launched a fully-automated multiomics application for fixed-frozen tissue and published its 2024 Corporate Sustainability Report. ### What is Bio-Techne's market position? Bio-Techne is a global leader in life sciences reagents and spatial biology technologies with $11.6 billion in assets under management. The company holds strong market positions through its RNAscope platform (the leading RNA in situ hybridization technology), its extensive antibody portfolio through R&D Systems and Novus Biologicals, and its ProteinSimple analytical instruments business. Bio-Techne operates in two segments: Protein Sciences (75% of revenue) and Diagnostics and Genomics (25% of revenue). ### What are Bio-Techne's future plans? Bio-Techne plans to complete the acquisition of Wilson Wolf by 2027 and continue expanding its spatial biology capabilities through the integration of RNAscope and COMET technologies. The company is focused on advancing its multiomics solutions, growing its partnerships (including recent agreements with Leica Biosystems, Waters Corporation, and ALZpath), and continuing to launch approximately 800 new products annually. Bio-Techne aims to strengthen its position in personalized medicine diagnostics and neurodegenerative disease research while advancing its ESG initiatives. ## Tags b2b, healthtech, manufacturing, saas, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*